Lehrman Biopharma
To serve the needs of biotechnology and pharmaceutical
companies that are bringing important new therapeutics and
pharmaceutical technologies to market. Lehrman Biopharma
supports late stage research to maximize candidate developability,
solves technical issues affecting formulation and analytical
development, and supports CMC activities at all stages of clinical
development. More specifically, Lehrman Biopharma has:
While Lehrman Biopharma is primarily a single proprietor operation,additional experts in pharmacokinetics, clinical development,
medicinal chemistry and related areas have been contacted as
necessary and assembled into ad hoc teams to accomplish program
goals.
companies that are bringing important new therapeutics and
pharmaceutical technologies to market. Lehrman Biopharma
supports late stage research to maximize candidate developability,
solves technical issues affecting formulation and analytical
development, and supports CMC activities at all stages of clinical
development. More specifically, Lehrman Biopharma has:
 | Developed parenteral, oral and inhalable formulations for | |
| drug candidates that are in development to treat diabetes, infectious disease, and pain. Several of these formulations are currently being tested in nonclinical and clinical trials, | ||
| Managed efforts to manufacture drug substance and drug | |
| product via CMO organizations for Phase I and II clinical trials. | ||
| Developed analytical methods for product testing in | |
| collaboration with CROs. | ||
| Resolved solubility and stability issues that have been | |
| identified during product development. | ||
| Served as an expert witness |
While Lehrman Biopharma is primarily a single proprietor operation,
medicinal chemistry and related areas have been contacted as
necessary and assembled into ad hoc teams to accomplish program
goals.
Lehrman Biopharma
 |
| |
 |
| |
 |
| |
 |